The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD

Abstract Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis, is recognized across the world, though Canada has among the highest burdens of IBD in the world. The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) led a six-province study that demonstrate...

Full description

Saved in:
Bibliographic Details
Published inJournal of the Canadian Association of Gastroenterology Vol. 6; no. Supplement_2; pp. S9 - S15
Main Authors Coward, Stephanie, Benchimol, Eric I, Kuenzig, M Ellen, Windsor, Joseph W, Bernstein, Charles N, Bitton, Alain, Jones, Jennifer L, Lee, Kate, Murthy, Sanjay K, Targownik, Laura E, Peña-Sánchez, Juan-Nicolás, Rohatinsky, Noelle, Ghandeharian, Sara, Im, James H B, Davis, Tal, Weinstein, Jake, Goddard, Quinn, Gorospe, Julia, Bennett, Jennifer, Caplan, Léa, Bergevin, Maxime, Yang, Xin Yu, Mason, Kate, Sanderson, Rhonda, Brass, Colten, Kaplan, Gilaad G
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.09.2023
Subjects
Online AccessGet full text
ISSN2515-2084
2515-2092
2515-2092
DOI10.1093/jcag/gwad004

Cover

Abstract Abstract Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis, is recognized across the world, though Canada has among the highest burdens of IBD in the world. The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) led a six-province study that demonstrated the compounding prevalence of IBD in Canada from 400 per 100,000 in 2002 to 636 per 100,000 in 2014. The prevalence in 2023 is estimated at 825 per 100,000, meaning that over 320,000 people in Canada are living with IBD. Prevalence is forecasted to rise by 2.44% per year such that 1.1% of the population, 470,000 Canadians, will live with IBD by 2035. The overall incidence of IBD in 2023 is 30 per 100,000 person-years, indicating that over 11,000 Canadians will be newly diagnosed with IBD in 2023. Incidence is forecasted to rise by 0.58% per year up to 32.1 per 100,000 by 2035. The rising incidence of IBD is propelled by pediatric-onset IBD, which is rising by 1.23% per year from 15.6 per 100,000 in 2023 to 18.0 per 100,000 in 2035. In contrast, incidence rates among adults and seniors are relatively stable. Understanding the determinates of IBD has expanded through prospective cohort studies such as the Crohn’s and Colitis Canada Genetic, Environmental, Microbial (CCC-GEM) project. Consensus recommendations towards diet, lifestyle, behavioural and environmental modifications have been proposed by international organizations with the goal of optimizing disease control and ultimately preventing the development of IBD. Despite these efforts, Canadian healthcare systems will need to prepare for the rising number of people living with IBD. Lay Summary Inflammatory bowel disease (IBD) is a disease that causes the intestines to inflame. IBD is something that is found in every country around the world. We have the highest number of people with IBD in the world compared to the total population. In 2002, one in every 250 (119,000) Canadians had IBD. In 2023, one in every 121 (320,000) Canadians has IBD. By 2035, one in every 91 (470,000) Canadians will have IBD. Roughly 11,000 Canadians will develop IBD in 2023. Rates of children developing IBD are rising. The rates of adults developing IBD are not changing. The rates of seniors developing IBD are also not changing. New research looks for better ways to care for IBD. New research also looks for ways to prevent IBD. One such project is Crohn’s and Colitis Canada Genetic, Environmental, Microbial project. This research suggests diet and lifestyle changes to improve the lives of people with IBD. The same changes may help reduce the number of people who develop IBD.
AbstractList Inflammatory bowel disease (IBD), consisting of Crohn's disease and ulcerative colitis, is recognized across the world, though Canada has among the highest burdens of IBD in the world. The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) led a six-province study that demonstrated the compounding prevalence of IBD in Canada from 400 per 100,000 in 2002 to 636 per 100,000 in 2014. The prevalence in 2023 is estimated at 825 per 100,000, meaning that over 320,000 people in Canada are living with IBD. Prevalence is forecasted to rise by 2.44% per year such that 1.1% of the population, 470,000 Canadians, will live with IBD by 2035. The overall incidence of IBD in 2023 is 30 per 100,000 person-years, indicating that over 11,000 Canadians will be newly diagnosed with IBD in 2023. Incidence is forecasted to rise by 0.58% per year up to 32.1 per 100,000 by 2035. The rising incidence of IBD is propelled by pediatric-onset IBD, which is rising by 1.23% per year from 15.6 per 100,000 in 2023 to 18.0 per 100,000 in 2035. In contrast, incidence rates among adults and seniors are relatively stable. Understanding the determinates of IBD has expanded through prospective cohort studies such as the Crohn's and Colitis Canada Genetic, Environmental, Microbial (CCC-GEM) project. Consensus recommendations towards diet, lifestyle, behavioural and environmental modifications have been proposed by international organizations with the goal of optimizing disease control and ultimately preventing the development of IBD. Despite these efforts, Canadian healthcare systems will need to prepare for the rising number of people living with IBD.
Inflammatory bowel disease (IBD), consisting of Crohn's disease and ulcerative colitis, is recognized across the world, though Canada has among the highest burdens of IBD in the world. The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) led a six-province study that demonstrated the compounding prevalence of IBD in Canada from 400 per 100,000 in 2002 to 636 per 100,000 in 2014. The prevalence in 2023 is estimated at 825 per 100,000, meaning that over 320,000 people in Canada are living with IBD. Prevalence is forecasted to rise by 2.44% per year such that 1.1% of the population, 470,000 Canadians, will live with IBD by 2035. The overall incidence of IBD in 2023 is 30 per 100,000 person-years, indicating that over 11,000 Canadians will be newly diagnosed with IBD in 2023. Incidence is forecasted to rise by 0.58% per year up to 32.1 per 100,000 by 2035. The rising incidence of IBD is propelled by pediatric-onset IBD, which is rising by 1.23% per year from 15.6 per 100,000 in 2023 to 18.0 per 100,000 in 2035. In contrast, incidence rates among adults and seniors are relatively stable. Understanding the determinates of IBD has expanded through prospective cohort studies such as the Crohn's and Colitis Canada Genetic, Environmental, Microbial (CCC-GEM) project. Consensus recommendations towards diet, lifestyle, behavioural and environmental modifications have been proposed by international organizations with the goal of optimizing disease control and ultimately preventing the development of IBD. Despite these efforts, Canadian healthcare systems will need to prepare for the rising number of people living with IBD.Inflammatory bowel disease (IBD), consisting of Crohn's disease and ulcerative colitis, is recognized across the world, though Canada has among the highest burdens of IBD in the world. The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) led a six-province study that demonstrated the compounding prevalence of IBD in Canada from 400 per 100,000 in 2002 to 636 per 100,000 in 2014. The prevalence in 2023 is estimated at 825 per 100,000, meaning that over 320,000 people in Canada are living with IBD. Prevalence is forecasted to rise by 2.44% per year such that 1.1% of the population, 470,000 Canadians, will live with IBD by 2035. The overall incidence of IBD in 2023 is 30 per 100,000 person-years, indicating that over 11,000 Canadians will be newly diagnosed with IBD in 2023. Incidence is forecasted to rise by 0.58% per year up to 32.1 per 100,000 by 2035. The rising incidence of IBD is propelled by pediatric-onset IBD, which is rising by 1.23% per year from 15.6 per 100,000 in 2023 to 18.0 per 100,000 in 2035. In contrast, incidence rates among adults and seniors are relatively stable. Understanding the determinates of IBD has expanded through prospective cohort studies such as the Crohn's and Colitis Canada Genetic, Environmental, Microbial (CCC-GEM) project. Consensus recommendations towards diet, lifestyle, behavioural and environmental modifications have been proposed by international organizations with the goal of optimizing disease control and ultimately preventing the development of IBD. Despite these efforts, Canadian healthcare systems will need to prepare for the rising number of people living with IBD.
Abstract Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis, is recognized across the world, though Canada has among the highest burdens of IBD in the world. The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) led a six-province study that demonstrated the compounding prevalence of IBD in Canada from 400 per 100,000 in 2002 to 636 per 100,000 in 2014. The prevalence in 2023 is estimated at 825 per 100,000, meaning that over 320,000 people in Canada are living with IBD. Prevalence is forecasted to rise by 2.44% per year such that 1.1% of the population, 470,000 Canadians, will live with IBD by 2035. The overall incidence of IBD in 2023 is 30 per 100,000 person-years, indicating that over 11,000 Canadians will be newly diagnosed with IBD in 2023. Incidence is forecasted to rise by 0.58% per year up to 32.1 per 100,000 by 2035. The rising incidence of IBD is propelled by pediatric-onset IBD, which is rising by 1.23% per year from 15.6 per 100,000 in 2023 to 18.0 per 100,000 in 2035. In contrast, incidence rates among adults and seniors are relatively stable. Understanding the determinates of IBD has expanded through prospective cohort studies such as the Crohn’s and Colitis Canada Genetic, Environmental, Microbial (CCC-GEM) project. Consensus recommendations towards diet, lifestyle, behavioural and environmental modifications have been proposed by international organizations with the goal of optimizing disease control and ultimately preventing the development of IBD. Despite these efforts, Canadian healthcare systems will need to prepare for the rising number of people living with IBD. Lay Summary Inflammatory bowel disease (IBD) is a disease that causes the intestines to inflame. IBD is something that is found in every country around the world. We have the highest number of people with IBD in the world compared to the total population. In 2002, one in every 250 (119,000) Canadians had IBD. In 2023, one in every 121 (320,000) Canadians has IBD. By 2035, one in every 91 (470,000) Canadians will have IBD. Roughly 11,000 Canadians will develop IBD in 2023. Rates of children developing IBD are rising. The rates of adults developing IBD are not changing. The rates of seniors developing IBD are also not changing. New research looks for better ways to care for IBD. New research also looks for ways to prevent IBD. One such project is Crohn’s and Colitis Canada Genetic, Environmental, Microbial project. This research suggests diet and lifestyle changes to improve the lives of people with IBD. The same changes may help reduce the number of people who develop IBD.
Author Bergevin, Maxime
Coward, Stephanie
Windsor, Joseph W
Bitton, Alain
Weinstein, Jake
Benchimol, Eric I
Peña-Sánchez, Juan-Nicolás
Kuenzig, M Ellen
Mason, Kate
Caplan, Léa
Jones, Jennifer L
Bernstein, Charles N
Sanderson, Rhonda
Brass, Colten
Im, James H B
Davis, Tal
Murthy, Sanjay K
Ghandeharian, Sara
Goddard, Quinn
Bennett, Jennifer
Gorospe, Julia
Rohatinsky, Noelle
Yang, Xin Yu
Kaplan, Gilaad G
Targownik, Laura E
Lee, Kate
Author_xml – sequence: 1
  givenname: Stephanie
  orcidid: 0000-0003-0675-7226
  surname: Coward
  fullname: Coward, Stephanie
– sequence: 2
  givenname: Eric I
  orcidid: 0000-0001-8855-3598
  surname: Benchimol
  fullname: Benchimol, Eric I
– sequence: 3
  givenname: M Ellen
  orcidid: 0000-0002-3984-8426
  surname: Kuenzig
  fullname: Kuenzig, M Ellen
– sequence: 4
  givenname: Joseph W
  orcidid: 0000-0002-7539-9103
  surname: Windsor
  fullname: Windsor, Joseph W
– sequence: 5
  givenname: Charles N
  orcidid: 0000-0001-8041-3574
  surname: Bernstein
  fullname: Bernstein, Charles N
– sequence: 6
  givenname: Alain
  surname: Bitton
  fullname: Bitton, Alain
– sequence: 7
  givenname: Jennifer L
  surname: Jones
  fullname: Jones, Jennifer L
– sequence: 8
  givenname: Kate
  surname: Lee
  fullname: Lee, Kate
– sequence: 9
  givenname: Sanjay K
  surname: Murthy
  fullname: Murthy, Sanjay K
– sequence: 10
  givenname: Laura E
  surname: Targownik
  fullname: Targownik, Laura E
– sequence: 11
  givenname: Juan-Nicolás
  orcidid: 0000-0002-4653-525X
  surname: Peña-Sánchez
  fullname: Peña-Sánchez, Juan-Nicolás
– sequence: 12
  givenname: Noelle
  orcidid: 0000-0003-3052-027X
  surname: Rohatinsky
  fullname: Rohatinsky, Noelle
– sequence: 13
  givenname: Sara
  surname: Ghandeharian
  fullname: Ghandeharian, Sara
– sequence: 14
  givenname: James H B
  surname: Im
  fullname: Im, James H B
– sequence: 15
  givenname: Tal
  surname: Davis
  fullname: Davis, Tal
– sequence: 16
  givenname: Jake
  surname: Weinstein
  fullname: Weinstein, Jake
– sequence: 17
  givenname: Quinn
  surname: Goddard
  fullname: Goddard, Quinn
– sequence: 18
  givenname: Julia
  surname: Gorospe
  fullname: Gorospe, Julia
– sequence: 19
  givenname: Jennifer
  surname: Bennett
  fullname: Bennett, Jennifer
– sequence: 20
  givenname: Léa
  surname: Caplan
  fullname: Caplan, Léa
– sequence: 21
  givenname: Maxime
  surname: Bergevin
  fullname: Bergevin, Maxime
– sequence: 22
  givenname: Xin Yu
  surname: Yang
  fullname: Yang, Xin Yu
– sequence: 23
  givenname: Kate
  surname: Mason
  fullname: Mason, Kate
– sequence: 24
  givenname: Rhonda
  surname: Sanderson
  fullname: Sanderson, Rhonda
– sequence: 25
  givenname: Colten
  surname: Brass
  fullname: Brass, Colten
– sequence: 26
  givenname: Gilaad G
  orcidid: 0000-0003-2719-0556
  surname: Kaplan
  fullname: Kaplan, Gilaad G
  email: ggkaplan@ucalgary.ca
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37674492$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1vEzEQxS1UREvojTOyxIEeCB1_bXZ7QTQtECkSl3K2xo6dOtq1l_UuVf77bkiIoBKcPJJ_72nevJfkJKboCHnN4AODSlxuLK4v1w-4ApDPyBlXTE05VPzkOJfylJznvAEAziTMhHpBTsWsmElZ8TOyvLt3lAMXdNG0aHuaPF1EX2PTYJ-6Lb1OD66mNyE7zI6GSOcYcYVX9LYNK9eEVKf19pfq-uYVee6xzu788E7I98-3d_Ov0-W3L4v5p-XUSqn6KRpRQcU88w4UoHC2ssDAICpWVKrwBgwXHIWwhTGsYgatl4YBGO9Lq8SEfNz7toNp3Mq62HdY67YLDXZbnTDov39iuNfr9FMzkLOyHNNOyMXBoUs_Bpd73YRsXV1jdGnImpcF5-PFOBvRt0_QTRq6OObTghVlIZXkcqTe_LnScZfflx6B93vAdinnzvkjwkDvutS7LvWhyxHnT3AbeuxD2gUK9b9E7_aiNLT_t38ETvaveQ
CitedBy_id crossref_primary_10_1016_j_clinbiochem_2025_110910
crossref_primary_10_1186_s13223_025_00953_8
crossref_primary_10_58931_cibdt_2024_2334
crossref_primary_10_3390_children11040481
crossref_primary_10_1080_19490976_2024_2409207
crossref_primary_10_3390_jcm13216476
crossref_primary_10_58931_cibdt_2024_2122
crossref_primary_10_7759_cureus_77941
crossref_primary_10_1093_ibd_izae081
crossref_primary_10_1016_j_ypmed_2024_108071
crossref_primary_10_7759_cureus_67672
crossref_primary_10_1093_ecco_jcc_jjae157
crossref_primary_10_1111_jcmm_18501
crossref_primary_10_1016_j_dld_2024_04_017
crossref_primary_10_32604_biocell_2024_057352
crossref_primary_10_3390_children10121904
crossref_primary_10_1016_j_heliyon_2024_e34932
Cites_doi 10.1053/j.gastro.2022.05.037
10.1136/bmj.n1554
10.1038/ajg.2015.52
10.1053/j.gastro.2019.01.002
10.1093/jcag/gwac036.035
10.1111/j.1572-0241.2006.00603.x
10.1038/nature11582
10.1053/j.gastro.2020.08.005
10.1016/j.cgh.2020.01.046
10.1053/j.gastro.2011.10.001
10.1038/nrgastro.2015.150
10.1038/s41575-020-00360-x
10.1053/j.gastro.2021.12.282
10.1053/j.gastro.2022.09.034
10.1016/S2468-1253(22)00021-8
10.1038/s41588-022-01156-2
10.1053/j.gastro.2021.07.009
10.1053/j.gastro.2016.10.020
10.1016/S0140-6736(17)32448-0
10.1016/j.cgh.2020.01.028
10.1097/MIB.0000000000000852
10.1136/gutjnl-2019-318936
10.2147/CLEP.S336517
10.1016/S2468-1253(21)00097-2
10.1016/S0016-5085(22)60984-3
10.1093/ibd/izab096
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. 2023
The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. 2023
– notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
– notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID TOX
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1093/jcag/gwad004
DatabaseName Oxford Journals Open Access Collection
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef
Publicly Available Content Database
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: TOX
  name: Oxford Journals Open Access Collection
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate The Impact of Inflammatory Bowel Disease in Canada 2023
EISSN 2515-2092
EndPage S15
ExternalDocumentID PMC10478802
37674492
10_1093_jcag_gwad004
10.1093/jcag/gwad004
Genre Journal Article
Review
GeographicLocations Canada
GeographicLocations_xml – name: Canada
GrantInformation_xml – fundername: ;
GroupedDBID 0R~
53G
7X7
8FI
8FJ
AAFWJ
AAPXW
AAVAP
ABEJV
ABGNP
ABPTD
ABUWG
ABXVV
ACGFS
ADBBV
AFKRA
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AMNDL
AOIJS
BAYMD
BCNDV
BENPR
CCPQU
EMOBN
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
ITC
KSI
ML0
M~E
O9-
OK1
PHGZM
PHGZT
PIMPY
RPM
TOX
UKHRP
AAYXX
CITATION
PUEGO
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c445t-ab39091f1fe050a3ec9c010baa516956fb0b232a33c6bb191bacf4b100bff8c53
IEDL.DBID 7X7
ISSN 2515-2084
2515-2092
IngestDate Tue Sep 30 17:12:41 EDT 2025
Thu Sep 04 15:46:44 EDT 2025
Fri Sep 19 20:51:41 EDT 2025
Thu Apr 03 07:07:15 EDT 2025
Wed Oct 01 03:17:12 EDT 2025
Thu Apr 24 23:00:52 EDT 2025
Fri May 23 09:42:24 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_2
Keywords Epidemiology trends
Prevalence
Crohn’s disease
Incidence
Ulcerative colitis
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0
The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c445t-ab39091f1fe050a3ec9c010baa516956fb0b232a33c6bb191bacf4b100bff8c53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-3052-027X
0000-0001-8041-3574
0000-0002-4653-525X
0000-0002-7539-9103
0000-0003-2719-0556
0000-0001-8855-3598
0000-0002-3984-8426
0000-0003-0675-7226
OpenAccessLink https://www.proquest.com/docview/3168645424?pq-origsite=%requestingapplication%
PMID 37674492
PQID 3168645424
PQPubID 7089191
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10478802
proquest_miscellaneous_2862200221
proquest_journals_3168645424
pubmed_primary_37674492
crossref_primary_10_1093_jcag_gwad004
crossref_citationtrail_10_1093_jcag_gwad004
oup_primary_10_1093_jcag_gwad004
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-09-01
PublicationDateYYYYMMDD 2023-09-01
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-01
  day: 01
PublicationDecade 2020
PublicationPlace US
PublicationPlace_xml – name: US
– name: England
– name: New York
PublicationTitle Journal of the Canadian Association of Gastroenterology
PublicationTitleAlternate J Can Assoc Gastroenterol
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Armstrong (2023110617112474500_CIT0023) 2023; 164
Sasson (2023110617112474500_CIT0021) 2021; 6
Narula (2023110617112474500_CIT0022) 2021; 374
Turpin (2023110617112474500_CIT0026) 2020; 159
Sazonovs (2023110617112474500_CIT0002) 2022; 54
Ananthakrishnan (2023110617112474500_CIT0011) 2020; 18
Jostins (2023110617112474500_CIT0003) 2012; 491
Coward (2023110617112474500_CIT0014) 2023; 6
Coward (2023110617112474500_CIT0009) 2019; 156
Kaplan (2023110617112474500_CIT0010) 2021; 18
Kaplan (2023110617112474500_CIT0001) 2017; 152
Bernstein (2023110617112474500_CIT0012) 2006; 101
Kaplan (2023110617112474500_CIT0005) 2015; 12
Pena-Sanchez (2023110617112474500_CIT0015) 2022; 28
Jones (2023110617112474500_CIT0017) 2019; 68
Ng (2023110617112474500_CIT0008) 2017; 390
Lee (2023110617112474500_CIT0025) 2021; 161
Turpin (2023110617112474500_CIT0027) 2022; 163
Cholapranee (2023110617112474500_CIT0004) 2016; 22
Levine (2023110617112474500_CIT0020) 2020; 18
Coward (2023110617112474500_CIT0016) 2022; 162
Benchimol (2023110617112474500_CIT0018) 2015; 110
Dhaliwal (2023110617112474500_CIT0019) 2021; 13
Kuenzig (2023110617112474500_CIT0007) 2022; 162
Ananthakrishnan (2023110617112474500_CIT0024) 2022; 7
Molodecky (2023110617112474500_CIT0006) 2012; 142
Windsor (2023110617112474500_CIT0013)
38106486 - J Can Assoc Gastroenterol. 2023 Nov 01;6(6):256. doi: 10.1093/jcag/gwad043
References_xml – volume: 163
  start-page: 685
  year: 2022
  ident: 2023110617112474500_CIT0027
  article-title: Mediterranean-like dietary pattern associations with gut microbiome composition and subclinical gastrointestinal inflammation
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2022.05.037
– volume: 374
  start-page: n1554
  year: 2021
  ident: 2023110617112474500_CIT0022
  article-title: Association of ultra-processed food intake with risk of inflammatory bowel disease: Prospective cohort study
  publication-title: BMJ
  doi: 10.1136/bmj.n1554
– volume: 110
  start-page: 553
  year: 2015
  ident: 2023110617112474500_CIT0018
  article-title: Inflammatory bowel disease in immigrants to Canada and their children: A population-based cohort study
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2015.52
– volume: 156
  start-page: 1345
  year: 2019
  ident: 2023110617112474500_CIT0009
  article-title: Past and future burden of inflammatory bowel diseases based on modeling of population-based data
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2019.01.002
– volume: 6
  start-page: 19
  year: 2023
  ident: 2023110617112474500_CIT0014
  article-title: Forecasting the incidence and prevalence of inflammatory bowel disease: A Canadian nation-wide analysis
  publication-title: J Can Assoc Gastroenterol
  doi: 10.1093/jcag/gwac036.035
– volume: 101
  start-page: 1559
  year: 2006
  ident: 2023110617112474500_CIT0012
  article-title: The epidemiology of inflammatory bowel disease in Canada: A population-based study
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2006.00603.x
– ident: 2023110617112474500_CIT0013
  article-title: The global evolution of inflammatory bowel disease across four epidemiologic stages: A systematic review of incidence and prevalence studies over the past century
  publication-title: Am J Gastroenterol
– volume: 491
  start-page: 119
  year: 2012
  ident: 2023110617112474500_CIT0003
  article-title: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
  publication-title: Nature
  doi: 10.1038/nature11582
– volume: 159
  start-page: 2092
  year: 2020
  ident: 2023110617112474500_CIT0026
  article-title: Increased intestinal permeability is associated with later development of Crohn’s disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.08.005
– volume: 18
  start-page: 1381
  year: 2020
  ident: 2023110617112474500_CIT0020
  article-title: Dietary guidance from the international organization for the study of inflammatory bowel diseases
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2020.01.046
– volume: 142
  start-page: 46
  year: 2012
  ident: 2023110617112474500_CIT0006
  article-title: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.10.001
– volume: 12
  start-page: 720
  year: 2015
  ident: 2023110617112474500_CIT0005
  article-title: The global burden of IBD: From 2015 to 2025
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2015.150
– volume: 18
  start-page: 56
  year: 2021
  ident: 2023110617112474500_CIT0010
  article-title: The four epidemiological stages in the global evolution of inflammatory bowel disease
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-020-00360-x
– volume: 162
  start-page: 1147
  year: 2022
  ident: 2023110617112474500_CIT0007
  article-title: Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: Systematic review
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2021.12.282
– volume: 164
  start-page: 228
  issue: 2
  year: 2023
  ident: 2023110617112474500_CIT0023
  article-title: Unfermented β-fructan fibers fuel inflammation in select inflammatory bowel disease patients
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2022.09.034
– volume: 7
  start-page: 666
  year: 2022
  ident: 2023110617112474500_CIT0024
  article-title: Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: An international organization for study of inflammatory bowel diseases consensus
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(22)00021-8
– volume: 54
  start-page: 1275
  year: 2022
  ident: 2023110617112474500_CIT0002
  article-title: Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
  publication-title: Nat Genet
  doi: 10.1038/s41588-022-01156-2
– volume: 161
  start-page: 1540
  year: 2021
  ident: 2023110617112474500_CIT0025
  article-title: Anti-microbial antibody response is associated with future onset of Crohn’s disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2021.07.009
– volume: 152
  start-page: 313
  year: 2017
  ident: 2023110617112474500_CIT0001
  article-title: Understanding and preventing the global increase of inflammatory bowel disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.10.020
– volume: 390
  start-page: 2769
  year: 2017
  ident: 2023110617112474500_CIT0008
  article-title: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)32448-0
– volume: 18
  start-page: 1252
  year: 2020
  ident: 2023110617112474500_CIT0011
  article-title: Changing global epidemiology of inflammatory bowel diseases: Sustaining health care delivery into the 21st century
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2020.01.028
– volume: 22
  start-page: 2191
  year: 2016
  ident: 2023110617112474500_CIT0004
  article-title: Environmental hygiene and risk of inflammatory bowel diseases: A systematic review and meta-analysis
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/MIB.0000000000000852
– volume: 68
  start-page: 1953
  year: 2019
  ident: 2023110617112474500_CIT0017
  article-title: IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-318936
– volume: 13
  start-page: 1109
  year: 2021
  ident: 2023110617112474500_CIT0019
  article-title: Incidence of inflammatory bowel disease in South Asian and Chinese people: A population-based cohort study from Ontario, Canada
  publication-title: Clin Epidemiol
  doi: 10.2147/CLEP.S336517
– volume: 6
  start-page: 754
  year: 2021
  ident: 2023110617112474500_CIT0021
  article-title: The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(21)00097-2
– volume: 162
  start-page: S-412
  issue: 7
  year: 2022
  ident: 2023110617112474500_CIT0016
  article-title: Forecasting the incidence and prevalence of inflammatory bowel disease: A Canadian nation-wide analysis
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(22)60984-3
– volume: 28
  start-page: 514
  year: 2022
  ident: 2023110617112474500_CIT0015
  article-title: Increasing prevalence and stable incidence rates of inflammatory bowel disease among first nations: Population-based evidence from a Western Canadian province
  publication-title: Inflamm Bowel Dis
  doi: 10.1093/ibd/izab096
– reference: 38106486 - J Can Assoc Gastroenterol. 2023 Nov 01;6(6):256. doi: 10.1093/jcag/gwad043
SSID ssj0002140735
Score 2.3844657
SecondaryResourceType review_article
Snippet Abstract Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis, is recognized across the world, though Canada has among the...
Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis, is recognized across the world, though Canada has among the highest...
Inflammatory bowel disease (IBD), consisting of Crohn's disease and ulcerative colitis, is recognized across the world, though Canada has among the highest...
SourceID pubmedcentral
proquest
pubmed
crossref
oup
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage S9
SubjectTerms Epidemiology
Inflammatory bowel disease
International organizations
Supplement
Title The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD
URI https://www.ncbi.nlm.nih.gov/pubmed/37674492
https://www.proquest.com/docview/3168645424
https://www.proquest.com/docview/2862200221
https://pubmed.ncbi.nlm.nih.gov/PMC10478802
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2515-2092
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002140735
  issn: 2515-2084
  databaseCode: DOA
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2515-2092
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002140735
  issn: 2515-2084
  databaseCode: M~E
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2515-2092
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002140735
  issn: 2515-2084
  databaseCode: RPM
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVASL
  databaseName: Oxford Journals Open Access Collection
  customDbUrl:
  eissn: 2515-2092
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002140735
  issn: 2515-2084
  databaseCode: TOX
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://academic.oup.com/journals/
  providerName: Oxford University Press
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2515-2092
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0002140735
  issn: 2515-2084
  databaseCode: 7X7
  dateStart: 20180201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2515-2092
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0002140735
  issn: 2515-2084
  databaseCode: BENPR
  dateStart: 20180201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LT9wwEB5RuPRSFUHbULpyJXqqonUS5-FeKhYWAWppVYG0t2jstXmIJrS7CPHvGTvewFZqe8nFEyXyjD0znvH3AeygzPkU0yrGEvNYSExiWWVFnFSGHDbFvJmHUvp6UhyeieNJPgkHbrPQVrnYE_1GPW21OyMfOoIlhz6Vis83v2LHGuWqq4FC4xmsJRSqOKsuJ2V_xpJS9lB6jk3y4jkZRCVC7zvl8cMrjefD8zuc8sDStvBKSzfdngScf_ZNPnFEBy_hRYgg2W6n8nVYMc0GfCF1M8dRzo78tUfWWnbUWFL3T19GZ6P2zlyz_a4cwy4b5mEJ8BMbP1LE3vu3RvubcHYwPt07jANRQqyFyOcxqkyS37eJNTznmBktNeVZCtFVwfLCKq4ocsIs04VSlKEp1FaohHNlbaXz7BWsNm1j3gArkWtVpEbJwgotBUqK6Cp3rYoiOS1MBB8XE1XrgCLuyCyu666andVuWuswrRF86KVvOvSMv8gxmvP_iGwvFFKHZTarH40igvf9MC0QV_XAxrS3szqlnM11oqRJBK87_fUfclA2Qsg0gmpJs72AA99eHmkuLzwIt4c1qni69e__egvPnfK7rrRtWJ3_vjXvKIyZq4G31QGsjcYn338M_GEAPU-_TR4AGTHz6g
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5V5QAXRMUr0FIj0ROK1nGch5EQatlWu3TbUyvtLdhepy0qSWG3WvVP8RuZcR7tIgGnnjNRopmxPeOZ-T6Ad1olfKZFHupMJ6FUOgpVHqdhlDs8sDHmjT2U0tFxOjqVX6bJdA1-dbMw1FbZ7Yl-o57Vlu7IB0SwROhTQn66-hESaxRVVzsKjcYtDt3NElO2-cfxEO27I8TB_snnUdiyCoRWymQRaoNpvorKqHQ84Tp2VllMSozWVDJK0tJwg2GGjmObGoPpjNG2lCbi3JRlboklArf8BzLmkrD6s2nW3-kIzFYyz-mJUUOCDpjLtteeq3jwzeqzwdlSz3jLCtedgiuTdXcC3D_7NO8cfAdP4HEbsbLdxsU2YM1VT2GC7sWIE52N_Zglq0s2rkp0r---bM_26qW7ZMOm_MMuKuZhEPQHtn9LSXvj39obPoPTe1Hhc1iv6sq9BJZpbk0qnFFpKa2SWmEEmdMYF0aOVroA3neKKmyLWk7kGZdFUz2PC1Jr0ao1gJ1e-qpB6_iLHEOd_0dkszNI0S7reXHrhAG87R_jgqQqi65cfT0vBOaI1PkiogBeNPbrP0TQOVIqEUC-YtlegMC-V59UF-ce9NvDKOVcvPr3f23Dw9HJ0aSYjI8PX8MjcoSmI24T1hc_r90WhlAL88b7LYOv971QfgOzbC4E
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+2023+Impact+of+Inflammatory+Bowel+Disease+in+Canada%3A+Epidemiology+of+IBD&rft.jtitle=Journal+of+the+Canadian+Association+of+Gastroenterology&rft.au=Coward%2C+Stephanie&rft.au=Benchimol%2C+Eric+I&rft.au=Kuenzig%2C+M+Ellen&rft.au=Windsor%2C+Joseph+W&rft.date=2023-09-01&rft.issn=2515-2092&rft.eissn=2515-2092&rft.volume=6&rft.issue=Suppl+2&rft.spage=S9&rft_id=info:doi/10.1093%2Fjcag%2Fgwad004&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2515-2084&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2515-2084&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2515-2084&client=summon